Definium Therapeutics (DFTX) Income towards Parent Company (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Income towards Parent Company data on file, last reported at -$57.0 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$57.0 million, down 87.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$187.5 million (down 80.3% YoY), and the FY2025 annual result was -$160.8 million, down 69.96% from the prior year.
• Income towards Parent Company retreated to -$57.0 million in Q1 2026 per DFTX's latest filing, from -$45.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $56.9 million in Q4 2022 and troughed at -$57.0 million in Q1 2026.
• A 5-year average of -$23.3 million and a median of -$21.8 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company jumped 104.95% in 2022, then slumped 137.83% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at $56.9 million in 2022, then sank by 137.83% to -$21.5 million in 2023, then slumped by 38.72% to -$29.8 million in 2024, then tumbled by 52.06% to -$45.4 million in 2025, then dropped by 25.54% to -$57.0 million in 2026.
• Business Quant data shows DFTX's Income towards Parent Company at -$57.0 million in Q1 2026, -$45.4 million in Q4 2025, and -$44.7 million in Q3 2025.